זוטקטרה - Zutectra
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | J06BB Specific immunoglobulins | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||||||||||||||
| צ×רת ××ª× | תת-×¢××¨× - S.C | ||||||||||||||||||||||||||||||
| צ×רת ××× ×× | ת×××¡× ×××רק×, SOLUTION FOR INJECTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||||||||||||||
| ×ת×××× | Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative adult patients at least one week after liver transplantation for hepatitis B induced liver failure.HBV-DNA negative status should be confirmed within the last 3 months prior to OLT. Patients should be HBsAg negative before treatment start.The concomitant use of adequate virostatic agents should be considered as standard of hepatitis B re-infection prophylaxis.
| ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×××ק××¨× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | BIOTEST PHARMA GMBH, GERMANY |
| ×©× ××¢× ×ר×ש×× | KAMADA LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 02/2012. ר×ש××× ×ת×ר××: 06/2018 |
| ת×ר×× ×¢×××× ××ר×× | 15/05/19 |
השינוי האחרון נעשה בֹ־17 במרץ 2014 ב־12:24